KREBSBIO · Krebs Biochemicals and Industries Ltd · Biotechnology & Drugs
KREBSBIO · Krebs Biochemicals and Industries Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
24.7% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹7 Cr
Revenue YoY
PAT YoY
+53.3%
Operating margin
Revenue, last 5 quarters
Source: Yahoo Finance, as of 30 Jun 2026
P/E (TTM)
P/B
Not available from data source
P/S (TTM)
Not available from data source
Sector P/E
Not available from data source
Dividend yield
Not available from data source
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| KREBSBIO (this stock) | Not meaningful (earnings negative over the last 12 months) | Not available from data source | -55.9% | Not available from data source | Not available from data source | Not available from data source |
| Sun Pharmaceutical Industries | 36.6 | 5.3 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
| Divi's Laboratories * | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 75.8 | 20 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
* Net margin, ROE, D/E and dividend yield for these companies come from RedixFi fundamentals; the data vendor had no values for them.
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| KREBSBIO | 2026-10-02 | 742 | 1 | STRONG | BULK |
| KREBSBIO | 2026-10-01 | 742 | 1 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
BSE and NSE imposed a fine of Rs. 5000 per day for 33 days due to non-compliance with Reg 17(1) of SEBI (LODR) Regulations, 2015 (board composition) from 1st January 2025 to 3rd February 2025.
Routine disclosures
Contingent Liability
1 occurrenceEarlier (1-3 years ago)
The company has contingent liabilities including income tax demands of Rs.723.75 lakhs and interest of Rs.334.65 lakhs, customs duty demands of Rs.144.58 lakhs, and employee provident fund damages of Rs.129.93 lakhs, among others.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company has disclosed related parties including promoters, directors, and M/s. Ipca Laboratories Ltd., which may indicate potential related-party transactions.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has outstanding statutory dues for income tax, customs duty, and other taxes, with disputes pending in various courts and tribunals, including amounts totaling over Rs. 3.74 crore for AY 2003-04 and Rs. 4.35 crore for AY 2022-23.
Management & Board Governance
1 occurrenceEarlier (1-3 years ago)
The company failed to appoint an Independent Director before the completion of Mr. G V L Prasad's tenure, but rectified the non-compliance by appointing four new Independent Directors on 4th February 2025.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.97% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).